Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
EXAS Stock Chart & Stats
$103.32
-$1.49(-2.61%)
At close: 4:00 PM EST
$103.32
-$1.49(-2.61%)
Day’s Range― - ―
52-Week Range$38.81 - $103.42
Previous CloseN/A
Volume846.89K
Average Volume (3M)2.21M
Market Cap
$19.69B
Enterprise Value$21.37B
Total Cash (Recent Filing)$1.00B
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Feb 24, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding190,810,200
10 Day Avg. Volume2,461,691
30 Day Avg. Volume2,212,738
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)4.31
Price to Sales (P/S)3.75
P/FCF Ratio138.84
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue6.93
Enterprise Value/Gross Profit10.29
Enterprise Value/Ebitda-28.43
Forecast
1Y Price Target
$103.57Price Target Upside0.24% Upside
Rating ConsensusHold
Number of Analyst Covering19
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition Premium And Shareholder ValueABT's offer of $105 per share represents a substantial premium to pre-deal prices, delivering clear value realization for Exact Sciences shareholders.
Commercial Momentum And Product PipelineReaccelerated Cologuard screening volumes, early CMS coverage for Oncodetect, and a leading MRD pipeline position the business to capture significant share in the expanding cancer diagnostics market.
Strategic Expansion Into Oncology DiagnosticsThe acquisition adds a major oncology diagnostics vertical and is expected to expand the combined company's total addressable market by more than forty billion dollars, creating new growth opportunities.
Bears Say
Deal Size Deters Competing BidsThe large transaction value and scale of the deal reduce the likelihood of a higher competing bidder emerging, capping the chance of a takeover-driven price increase.
Limited Upside For Remaining InvestorsShares trading at or near the proposed acquisition price significantly limit upside potential, prompting analyst downgrades to hold or neutral.
Near-term Dilution And Integration RiskAnalysts flag expected dilution in 2026 and 2027 and potential integration challenges as factors that could pressure near-term earnings and execution for the combined company.
Exact Sciences News
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $38.81 and its highest was $103.42 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Exact Sciences Corp.’s market cap is $19.69B.
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is Feb 24, 2026 which is in 14 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on Nov 03, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.061 by -$0.039.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -0.11.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 190,810,200 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.061. Following the earnings report the stock price went up 3.897%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Currently, no hedge funds are holding shares in EXAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exact Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$103.57 (0.24% Upside)
$103.57 (0.24% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.08%
12-Months-Change
Fundamentals
Return on Equity
-34.54%
Trailing 12-Months
Asset Growth
-12.57%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXAS Company Deck
EXAS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Exact Sciences reported strong financial and operational performance with significant revenue growth driven by Cologuard and new product launches. However, there were challenges in maintaining gross margins and completing payer contracts for Cologuard Plus.View all EXAS earnings summariesEXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
EXAS Stock 12 Month Forecast
Average Price Target
$103.57
▲(0.24% Upside)
Technical Analysis
Ownership Overview
1.20% Insiders
36.62% Mutual Funds
0.86% Other Institutional Investors
48.80% Public Companies and
Individual Investors